ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Systemic"

  • Abstract Number: 1377 • ACR Convergence 2021

    Assessment of Autoantibodies and Clinical Associations in SSc Patients with ANA Positivity & Negative for Prototypic Autoantibodies

    Karen Kruzer1, Roberta G Marangoni1, Ilana Heckler2, Aya Elhage2, Varga John3, Monique Hinchcliff4, Mary Carns5, Kathleen Aren5, Amy Wielgosz1, Marc Nuzzo6, Iswariya Venkataraman2 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2EUROIMMUN US, Mountain Lakes, NJ, 3University of Michigan, Ann Arbor, MI, 4Yale School of Medicine, Westport, CT, 5Northwestern University Division of Rheumatology, Chicago, IL, 6Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic sclerosis (SSc) is a clinically heterogenous disease typically characterized by a positive ANA (ANA+), and prototypical antibodies including anti-centromere, anti-topoisomerase, and anti-RNA polymerase…
  • Abstract Number: 0413 • ACR Convergence 2021

    Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort

    Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada

    Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
  • Abstract Number: 1379 • ACR Convergence 2021

    Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis

    Isabella Atzeni1, Yehya Al-Adwi2, Berber Doornbos-van der Meer2, Anniek Van Roon2, Caroline Roozendaal1, Andries Smit2, Alja J. Stel2, Harry Van Goor2, Tji-Joong Gan1, Johanna Westra2 and Douwe J Mulder2, 1University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, 2University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
  • Abstract Number: 0500 • ACR Convergence 2021

    Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin

    Monica Yang1, Vivien Goh2, Monica Espinoza3, Yiwei Yuan4, Julia Lee5, Mary Carns6, Dinesh Khanna7, Zsuzsanna McMahan8, Michael Whitfield9 and Monique Hinchcliff10, 1University of California San Francisco, San Francisco, CA, 2Northwestern University, Chicago, IL, 3Geisel School of Medicine, Hanover, NH, 4Dartmouth College, Hanover, NH, 5Northwestern University Feinberg School of Medicine, Chicago, IL, 6Northwestern University Division of Rheumatology, Chicago, IL, 7University of Michigan, Ann Arbor, MI, 8Johns Hopkins Rheumatology, Baltimore, MD, 9Geisel School of Medicine, Lebanon, NH, 10Yale School of Medicine, Westport, CT

    Background/Purpose: Although two subsets in systemic sclerosis (SSc) have been identified based on degree of skin disease, the current classification system, limited vs. diffuse cutaneous,…
  • Abstract Number: 1382 • ACR Convergence 2021

    Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis

    Sabrina Hoa1, Murray Baron2 and Marie Hudson3, 1Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, 2Jewish General Hospital, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
  • Abstract Number: 0541 • ACR Convergence 2021

    N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis

    Runa Kuley1, Ryan Stultz2, Bhargavi Duvvuri2, Roger Hesselstrand3, J Lee Nelson4 and Christian Lood2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of Washington, Seattle, WA, 3Lund University, Lund, Sweden, 4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

    Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease, and its etiology is unknown. Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs)…
  • Abstract Number: 1383 • ACR Convergence 2021

    Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model

    Alexandru Garaiman1, Klaus Steigmiller2, Catherine Gebhard3, Marco Matucci-Cerinic4, Jorg Henes5, Jeska de Vries-Bouwstra6, Vanessa Smith7, Andrea Doria8, Yannick Allanore9, Lorenzo Dagna10, Branimir Anic11, Carlomaurizio Montecucco12, Otylia Kowal-Bielecka13, Mickael Martin14, Yoshiya Tanaka15, Anna-Maria Hoffmann-Vold16, Ulrike Held2, Oliver Distler17 and Mike Oliver Becker18, 1University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Zurich, Switzerland, 3Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 4University of Florence, Florence, Italy, 5University Hospital Tuebingen, Tuebingen, Germany, 6Leiden University Medical Center, Leiden, Netherlands, 7Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, 8University of Padova, Padova, Italy, 9Université de Paris, Paris, France, 1010Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy, 11Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, 12Department of Rheumatology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, 13Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 14Internal Medicine, Poitiers University Hospital, Poitiers, France, 15University of Occupational and Environmental Health, Kitakyushu, Japan, 16Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 17Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 18Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Background/Purpose: Digital ulcers (DUs) affect half of the patients with systemic sclerosis (SSc) and can be complicated by gangrene and amputation. Platelets are known to…
  • Abstract Number: 0544 • ACR Convergence 2021

    Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis

    Eliza Pei-Suen Tsou, M.Asif Amin, Phillip Campbell, Mikel Gurrea-Rubio, Morgan Omara, Ellen Model, Pamela Palisoc, Mustafa Ali, Sirapa Vichaikul, Jonatan Hervoso, Jeffrey Ruth, Dinesh Khanna and David Fox, University of Michigan, Ann Arbor, MI

    Background/Purpose: Aminopeptidase N, also known as CD13, is a Zn2+-dependent membrane bound ectopeptidase widely expressed in mammalian cells including rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS),…
  • Abstract Number: 1389 • ACR Convergence 2021

    Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases

    Anna-Maria Hoffmann-Vold1, Helena Andersson2, Silje Reiseter2, Håvard Fretheim2, Imon Barua1, Torhild Garen3, Øyvind Midtvedt1, Ragnar Gunnarsson2, Michael Durheim2, Trond Mogens AAløkken2 and Øyvind Molberg1, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Department of Rheumatology, Oslo University Hospital, Oslo, Nepal

    Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
  • Abstract Number: 0545 • ACR Convergence 2021

    SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells

    Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
  • Abstract Number: 1390 • ACR Convergence 2021

    A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis

    Alicia Hinze1, Shreyasee Amin1, Ashima Makol1, Robert Vassallo1, Cynthia Crowson2 and Brian Bartholmai1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

    Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 1437 • ACR Convergence 2021

    Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis

    Nancy Wareing1, Brian Skaug2, Minghua Wu3, Scott Collum1, Cory Wilson1, Lucy Revercomb4, Marka Lyons5, Weizhen Bi6, Tingting Mills1, Julio Charles5, Shervin Assassi1 and Harry Karmouty-Quintana1, 1University of Texas McGovern Medical School at Houston, Houston, TX, 2University of Texas McGovern Medical School Houston, Houston, TX, 3University of Texas Health Science Center at Houston, Houston, TX, 4Rice University, Houston, TX, 5Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, 6McGovern Medical School at UTHealth, Houston, TX

    Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…
  • Abstract Number: 0548 • ACR Convergence 2021

    Rapamycin Blocks the Profibrotic Effects of Fli1 Downregulation in Scleroderma Myeloid Cells

    Fatima El-adili, Grace Marden, Maria Trojanowska and Andreea Bujor, Boston University School of Medicine, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune fibrotic disease with unclear pathogenesis and no effective therapies. Increased proportion of CD163-positive, profibrotic macrophages has been described…
  • Abstract Number: 1836 • ACR Convergence 2021

    Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis

    Julia Spierings1, Svetlana Nihtyanova2, Emma Derrett-Smith3, Kristina Clark2, Jacob van Laar4, Voon Ong5 and Christopher Denton6, 1University Medical Center Utrecht, Utrecht, Netherlands, 2University College London, Royal Free Campus, London, United Kingdom, 3University College London Division of Medicine, London, United Kingdom, 4University Medical Centre Utrecht, Utrecht, Netherlands, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Autologous haematopoietic stem cell transplantation (SCT) has emerged as an effective treatment for patients with severe diffuse systemic sclerosis (dcSSc) based upon the results…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology